About Pulse Biosciences
Pulse Biosciences is a company based in Burlingame (United States) founded in 2014 was acquired by unknown in July 2021. It operates as a HealthTech. Pulse Biosciences has raised $8 million across 4 funding rounds from investors including Bob Duggan and unknown. The company has 75 employees as of December 31, 2024. Pulse Biosciences offers products and services including nPulse™ Vybrance™ Percutaneous Ablation System, nsPFA™ Cardiac Surgery Ablation System, and nsPFA™ 360 Catheter Endocardial Ablation System. Pulse Biosciences operates in a competitive market with competitors including Novocure, Kardium, Argá Medtech, QV Bioelectronics and Adagio Medical, among others.
- Headquarter Burlingame, United States
- Employees 75 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Pulse Biosciences, Inc
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-53.59 M-26.95as on Dec 31, 2024
-
EBITDA
$-53.18 M-25.53as on Dec 31, 2024
-
Total Equity Funding
$8 M (USD)
in 4 rounds
-
Latest Funding Round
$65 M (USD), Post-IPO
May 01, 2023
-
Investors
& 1 more
-
Employee Count
75
as on Dec 31, 2024
-
Acquired by
unknown
(Jul 01, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pulse Biosciences
Pulse Biosciences is a publicly listed company on the NASDAQ with ticker symbol PLSE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pulse Biosciences
Pulse Biosciences offers a comprehensive portfolio of products and services, including nPulse™ Vybrance™ Percutaneous Ablation System, nsPFA™ Cardiac Surgery Ablation System, and nsPFA™ 360 Catheter Endocardial Ablation System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Used for nonthermal ablation of benign thyroid nodules.
Designed for surgical cardiac ablation with nonthermal energy.
Applied for pulmonary vein isolation in atrial fibrillation.
Unlock access to complete
Funding Insights of Pulse Biosciences
Pulse Biosciences has successfully raised a total of $8M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $65.0M
-
First Round
First Round
(11 Nov 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Post-IPO - Pulse Biosciences | Valuation |
investors |
|
| Sep, 2017 | Amount | Post-IPO - Pulse Biosciences | Valuation |
investors |
|
| Feb, 2017 | Amount | Post-IPO - Pulse Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pulse Biosciences
Pulse Biosciences has secured backing from 2 investors, including angel investors. Prominent investors backing the company include Bob Duggan and unknown. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BD
Bob Duggan |
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pulse Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pulse Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pulse Biosciences Comparisons
Competitors of Pulse Biosciences
Pulse Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novocure, Kardium, Argá Medtech, QV Bioelectronics and Adagio Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for solid tumors are developed via Tumor Treating Fields.
|
|
| domain | founded_year | HQ Location |
Atrial fibrillation ablation devices are developed by Kardium.
|
|
| domain | founded_year | HQ Location |
Medical devices for cardiac arrhythmias are developed by Argá Medtech.
|
|
| domain | founded_year | HQ Location |
Electrotherapy devices for brain tumor treatment are manufactured.
|
|
| domain | founded_year | HQ Location |
Cardiovascular therapies are developed by Adagio Medical in stealth mode.
|
|
| domain | founded_year | HQ Location |
Develops innovative devices for bimodal electric tissue ablation.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pulse Biosciences
Frequently Asked Questions about Pulse Biosciences
When was Pulse Biosciences founded?
Pulse Biosciences was founded in 2014.
Where is Pulse Biosciences located?
Pulse Biosciences is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Is Pulse Biosciences a funded company?
Pulse Biosciences is a funded company, having raised a total of $8M across 4 funding rounds to date. The company's 1st funding round was a Post-IPO of $5M, raised on Nov 11, 2014.
How many employees does Pulse Biosciences have?
As of Dec 31, 2024, the latest employee count at Pulse Biosciences is 75.
What does Pulse Biosciences do?
Pulse Biosciences is focused on the research, design, and production of proprietary Nanosecond Pulse Field Ablation (nsPFA) technology, branded as nPulse, for high-impact healthcare applications. The company is dedicated to soft tissue ablation, including treatments for benign thyroid nodules, and cardiac ablation for conditions like atrial fibrillation. Solutions are developed across medical sectors, aiming to provide nonthermal, minimally invasive alternatives to conventional treatments. Their innovative devices, such as the nsPFA Cardiac Surgery Ablation System and nPulse Vybrance Percutaneous Ablation System, are positioned to improve patient outcomes in electrophysiology and other therapeutic areas.
Who are the top competitors of Pulse Biosciences?
Pulse Biosciences's top competitors include Kardium, Adagio Medical and Novocure.
What products or services does Pulse Biosciences offer?
Pulse Biosciences offers nPulse™ Vybrance™ Percutaneous Ablation System, nsPFA™ Cardiac Surgery Ablation System, and nsPFA™ 360 Catheter Endocardial Ablation System.
Is Pulse Biosciences publicly traded?
Yes, Pulse Biosciences is publicly traded on NASDAQ under the ticker symbol PLSE.
Who are Pulse Biosciences's investors?
Pulse Biosciences has 2 investors. Key investors include Bob Duggan, and unknown.
What is Pulse Biosciences's ticker symbol?
The ticker symbol of Pulse Biosciences is PLSE on NASDAQ.